Australia, [23.08.2024] - B. Braun Australia, a leading medical technology company and one of the key players in the healthcare sector, is stepping up proactively to support the healthcare system during the ongoing national shortage of IV fluids.

Although its supply chain remains unaffected, the Company recognises the growing need across the country and acted swiftly to secure additional stock of intravenous (IV) fluids. These supplies, approved by the Therapeutic Goods Administration (TGA) under Section 19A, are intended to help alleviate the pressure on healthcare providers during this critical time (https://www.tga.gov.au/about-IV-fluids-shortages). 

“We understand the urgency of the situation and the importance of maintaining a steady supply of IV fluids, especially during times of heightened demand,” said Geoff Brown, Managing Director at B. Braun Australia. “Our team has worked diligently to obtain the necessary approvals and secure additional stock to ensure healthcare facilities can continue to deliver quality patient care.”

With this initiative to address the shortage, B. Braun Australia reaffirms its commitment to help improve and protect the health of people around the world. By prioritising the needs of the healthcare system and taking decisive actions to address supply limitations, B. Braun underscores its dedication to the well-being of patients and the healthcare community at large.